Joshua K. Sabari, MD, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer and an exon 20 insertion.
Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Grossman School of Medicine, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer (NSCLC) and an exon 20 insertion.
The standard of care for patients with EGFR-mutant disease is chemotherapy combination therapy which has been shown to achieve a median survival of about 7 months. According to Sabari, the survival rate reveals a need for more effective treatment overall.
The landscape for those with an exon 20 insertion is less populated with effective agents, says Sabari. These patients do not respond to treatment with traditional tyrosine kinase inhibitors like those with exon 19 and 21 insertions tend to respond. More exon 20-specific inhibitor are needed in the space. Further, there is a need for therapies with better safety profiles for patients with EGFR-mutant and exon 20 insertion-positive NSCLC.
CNS Activity of Third-Generation ALK TKIs Influence Approach in NSCLC
June 21st 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.
Read More
Differences in TKIs May Sway Choice of First-Line Therapy in ALK+ NSCLC
May 21st 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, asked participants their perspectives on the use of targeted agents for patients with ALK+ non–small cell lung cancer in the second article of a 2-part series.
Read More
Bispecific Combination Therapy Leads Paradigm Shift in Advanced NSCLC
May 20th 2024This case-based feature focused on oncologists at 2 virtual events who examined the development of new EGFR-targeted therapies including combinations of amivantamab with lazertinib and with chemotherapy.
Read More